TEL AVIV, Israel, - July 30, 2010 (CRWE NEWSWIRE) - mBeach Software Inc. (”MBHS”) (OTCBB:MBHS - News) today announced a strategy of targeting new international market opportunities. In particular, the company has identified the emerging markets of Russia and Commonwealth of Independent States (CIS)
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.
According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
mBeach CEO Yossi Biderman commented, “One of the main reasons for relatively high cancer death rates in Russia and CIS is that patients are often diagnosed with the disease once it is too late. This is a very large and growing healthcare market and represents an important opportunity for Skin Cancer Scanning (SCS), our wholly owned subsidiary company. Our simple-to-use, non-invasive, point-of-care, skin cancer detection solution is ideally suited for this market.”
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor’s office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS’ products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Contact:
mBeach Software Inc.
Mr. Yossi Biderman, CEO
+ 972 36353532
info@scs-med.com
******************************************************************
CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup
About CRWENewswire.com
CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.
CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.
